Royalty Pharma (RPRX) announced the appointment of Vlad Coric to the company’s board of directors, effective immediately. Vlad Coric is the chairman and CEO of Biohaven (BHVN).
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RPRX:
- Royalty Pharma pullback a buying opportunity, says Citi
- Royalty Pharma’s Strong Portfolio and Future Growth Potential Underpin Buy Rating
- Royalty Pharma’s Internalization Strategy: Navigating Risks and Uncertainties Ahead of 2025 Transition
- Royalty Pharma announces R&D funding collaboration with Biogen
- Royalty Pharma PLC Reports Strong 2024 Financial Results